Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Accurately Predicts Prematurity Complications in Newborns from Blood Samples

By LabMedica International staff writers
Posted on 27 Jan 2026

Premature birth is a leading cause of infant illness and long-term disability. More...

However, doctors still struggle to predict which newborns will develop serious complications affecting the brain, lungs, eyes, or digestive system. Babies born at the same gestational age and weight can follow very different medical paths, making early clinical decision-making difficult. Researchers have now shown that patterns hidden in routine blood samples collected shortly after birth can be used to forecast these medical trajectories, offering a way to anticipate and potentially prevent complications of prematurity.

Researchers from Stanford Medicine (Stanford, CA, USA) applied artificial intelligence (AI) to analyze biochemical data already collected through routine newborn screening programs. Using small blood spots obtained at birth, the AI model examined metabolic markers such as amino acids and fat breakdown products. These measurements were combined with basic clinical information to create a metabolic health index capable of distinguishing different biological forms of prematurity rather than treating all early births as a single condition.

The researchers analyzed data from 13,536 premature infants born in California and validated the results using an independent cohort of 3,299 preterm infants from Ontario, Canada. The AI system identified molecular patterns linked to four major prematurity complications, including lung, intestinal, eye, and brain disorders. The findings, published in Science Translational Medicine, showed that a set of six blood-based measurements, combined with clinical factors, predicted individual complications with more than 85 percent accuracy.

The findings suggest that prematurity is not a single condition but a collection of distinct biological pathways that lead to different outcomes. Early risk prediction could help determine which infants need specialized neonatal intensive care and allow physicians to tailor monitoring and treatment strategies from birth. Researchers plan to expand the model by integrating maternal health data, electronic medical records, and additional biological measurements, with the long-term goal of preventing complications before they fully develop.

“The goal is to have a whole new taxonomy of prematurity, so you can see where a child is headed and understand what is causing differences in their health trajectories,” said study co-author David Stevenson, MD, “That will allow us to intervene, prevent, and treat complications.”

Related Links:
Stanford Medicine


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Test
Allplex HPV28 Detection
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.